dostarlimab
gsk
[]
 why not observe and operate for progression? have you seen msi-h patients with a pr/sd after checkpoint rapidly progress beyond salvage?
Surgical oncologist and cancer immunologist. Views are my own and do not represent those of the National Cancer Institute.